New Developments in Alzheimer’s Treatment
At the recent Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, new findings from Biogen's Phase 2 CELIA study were unveiled, showcasing their investigational therapy, diranersen (BIIB080). This therapy aims to reduce tau production, a protein associated with the progression of Alzheimer's disease. The new data indicates that the clinical benefits of diranersen may enhance over time, potentially providing a beacon of hope for those affected by this challenging condition.
Laura Nisenbaum, PhD, the Interim Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF), emphasized the significance of this trial. She noted that it offers the first evidence from a randomized study suggesting that reducing tau levels can help slow cognitive decline in Alzheimer’s patients. The results presented imply that the positive effects of diranersen could increase with longer treatment periods. Specifically, participants receiving the lowest dose experienced a
38% slowdown in cognitive decline over a two-year period on the CDR-SB scale, which assesses cognition and daily functioning.
This new revelation builds upon earlier findings from July, where diranersen showed strong efficacy in reducing tau levels, despite not meeting its primary endpoint at that time. The recent data from the CELIA study illustrates a clear trend of improved outcomes, establishing a pathway for further investigation.
Nisenbaum highlighted the need for larger Phase 3 trials to further validate these findings, as the safety and clinical efficacy of diranersen need thorough evaluation in broader patient populations. Optimistically, she pointed out that diranersen managed to lower tau without impacting amyloid levels, a crucial finding. This opens the door for potential combination therapies that may work synergistically to tackle Alzheimer’s disease from multiple angles.
The symposium also presented long-term data from the ongoing extension of the study, which monitored efficacy and safety over
96 weeks. The dosage that seemed to balance the benefits and potential side effects best was the lowest dose that participants received. Importantly, no new safety signals were detected, further reinforcing the therapy’s promise.
Efforts to combat Alzheimer’s are gaining momentum. Notably, the current clinical pipeline boasts
158 drugs in varying stages of trials, with nearly 75% aiming to address biology beyond just amyloid and tau. This shift marks a significant advancement in the understanding of Alzheimer's disease, aligning with efforts observed in cancer therapies, where combination treatments are tailored to individual patient needs.
Isobel Coleman, CEO of ADDF, shared her insights, asserting that each new dataset on tau is pivotal in moving closer to personalized Alzheimer’s treatment. With a dedicated focus on targets that extend beyond amyloid, the ADDF is committed to advancing research that fulfills the promise of precision medicine for those living with Alzheimer’s.
The Alzheimer’s Drug Discovery Foundation, established in 1998, has poured significant resources into fostering drug development specifically for Alzheimer’s. Using a venture philanthropy model, it supports innovative drug research, contributing to impressive advancements such as the first Alzheimer’s PET scan and blood tests. To date, the foundation has allocated nearly
$400 million towards various Alzheimer’s drug development and biomarker projects across
21 countries.
As the medical community eagerly awaits the results of future Phase 3 trials, the insights gleaned at the CTAD conference signal a transformative era in tackling Alzheimer’s disease, steering towards a future where combination therapy approaches may drastically change patient outcomes.
For more information about the Alzheimer's Drug Discovery Foundation and its initiatives, visit
alzheimer’sdiscovery.org or explore how philanthropy can lead to breakthroughs in Alzheimer’s research.